Vir Biotechnology Inc
VIR
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.79B
Close$
$12.26
13.9% upside
Current Fair Value
13.9% upsideUndervalued by 13.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.79 Billion |
|---|---|
| Enterprise Value | $1.61 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.16 |
| Beta | 1.63 |
| Outstanding Shares | 167,719,015 |
Return
| Return on Equity | -25.62% |
|---|---|
| Return on Assets | -20.72% |
| Return on Invested Capital | -24.39% |
Valuation & Multiples
| P/E Ratio | -5.74 |
|---|---|
| PEG | 3.33 |
| Price to Sales | 10.77 |
| Price to Book Ratio | 2.15 |
| Enterprise Value to Revenue | 5.3 |
| Enterprise Value to EBIT | -5.88 |
| Enterprise Value to Net Income | -7 |
| Total Debt to Enterprise | 0.06 |
| Debt to Equity | 0.09 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$0.33
Average shareholder expectationRevenue Estimate
$135.88 M
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$-0.75
Average shareholder expectationRevenue Estimate
$956,500
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.5413▼ 38.42% |
|---|---|
| Total Calls | 337,900▼ 5.44% |
| Total Puts | 182,900▼ 44.69% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 88.20%▼ 6.48% |
|---|---|
| Total Invested | $1.51B▲ 20.70% |
| Investors Holding | 246▼ 17.00% |
ESG Score
No data
About Vir Biotechnology Inc
327 employeesVir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are desi...